Prostate News Archive
22-Oct-2008
Ariad's partner Merck initiates Phase II prostate cancer trial (Pharmaceutical Business Review)
Ariad Pharmaceuticals, a developer of medicines to treat cancer, has announced the initiation of a Phase II clinical trial by Merck & Co to evaluate the safety and efficacy of oral deforolimus, Ariads investigational mTOR inhibitor, in patients with advanced prostate cancer. Lockerbie bomber dying of prostate cancer (Daily Record)
THE Lockerbie bomber is battling "advanced stage" cancer, his lawyer said today. Abdelbaset Ali Mohmed Al Megrahi was diagnosed with prostate cancer after hospital tests last month and the disease has spread to other parts of his body, solicitor Tony Kelly said. Interim Phase II Results Support Efficacy Of CB7630 (Abiraterone Acetate) In Advanced Prostate Cancer Patients (Medical News Today)
Cougar Biotechnology, Inc. (NASDAQ:CGRB) today announced that results from an ongoing Phase II clinical trial of Cougar's investigational drug CB7630 (abiraterone acetate) were presented today at the prostate Cancer Foundation Scientific Retreat. The prostate Cancer Foundation Scientific Retreat is currently taking place in Lake Tahoe, Nevada.
Back to Prostate News Archive
